Signification of protein p-53 isoforms and immune therapeutic success in chronic lymphocytic leukemia

• Published in: Biomedicine & pharmacotherapy 2018-10, Vol.106, p.50-53
• Main Authors: Udristioiu, Aurelian, Nica-Badea, Delia
• Format: Article
• Language: English
• Subjects: Animals; Anti-PD therapeutic agents; Antineoplastic Agents, Immunological - therapeutic use; Aurora kinase; B7-H1 Antigen - antagonists & inhibitors; B7-H1 Antigen - immunology; B7-H1 Antigen - metabolism; Chronic lymphocytic leukemia; CTLA-4 Antigen - antagonists & inhibitors; CTLA-4 Antigen - immunology; CTLA-4 Antigen - metabolism; DNA Damage; Humans; Immunotherapy - methods; Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy; Leukemia, Lymphocytic, Chronic, B-Cell - genetics; Leukemia, Lymphocytic, Chronic, B-Cell - immunology; Leukemia, Lymphocytic, Chronic, B-Cell - metabolism; m-TOR; Molecular Targeted Therapy; Mutation; P-53 protein isoform; Precision Medicine; Programmed Cell Death 1 Receptor - antagonists & inhibitors; Programmed Cell Death 1 Receptor - immunology; Programmed Cell Death 1 Receptor - metabolism; Protein Isoforms; Treatment Outcome; Tumor Suppressor Protein p53 - genetics; Tumor Suppressor Protein p53 - metabolism
• ISSN: 0753-3322; 1950-6007
• DOI: 10.1016/j.biopha.2018.06.072

[Display omitted] •Review of p53 mutations occurring different cellular mechanisms in CLL.•Altered activity isoform p-53 protein lead impairs DNA damage and cancer phenotype.•Anti-PD therapy repair tumor-induced immune defects, antitumor immune reset. In the past few years has used thetechnique for analyzing deletions of genes, its rearrangements, cross-reactivity or multiplications in human genome affected of genetic diseases. Was proved that, the best techniques in the investigation of malignant lymphocytes are the Flow Cytometry, Elisa, ICT and Fluorescence in situ hybridization (FISH). Last method, FISH is used as an alternative to chromosomal banding, a conventional application in molecular medicine and can detect the chromosomal rearrangements and complexes of different genes in malignant diseases, like chronic lymphocytic leukemia (CLL), acute lymphocytic leukemia, (ALL), or multiple myeloma (MM). Identification of P53 gene deletions and mutations in regions of chromosome 17 in hematological malignancies is important because these mutations have an impact on the clinical management of patients.